| 1 |
RAPA-501
|
2/3 |
- no placebo
- autologous hybrid TREG/Th2 cells delivered intravenously
- site in MA
|
Rapa Therapeutics LLC |
| 2 |
STRO4
|
2 |
- no placebo
- autologous bone-marrow-derived mesenchymal stem cells delivered intravenously
- site in TX
|
New England Cell Therapeutics, Inc. |
| 3 |
Usnoflast
|
2 |
- 36 weeks study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of Usnoflast administered to adult subjects with Amyotrophic Lateral Sclerosis
- Followed by 16 weeks open label extension study
- sites in TX
|
Zydus Therapeutics Inc. |
| 4 |
PHENOGENE-1A (Cromolyn)
|
2 |
- Multifunctional therapy based on a repurposed drug, formulated with novel targeted delivery technology
- This approach is designed to achieve therapeutic concentrations in both blood and brain, where it acts on key mechanisms involved in neuroinflammation and neurodegeneration
- sites in CA, FL, NY
|
PhenoNet, Inc. |
| 5 |
COYA 302
|
2 |
- Combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages
- sites in GA, MA, MO, NE, TX,
|
Coya Therapeutics |
| 6 |
Vit E, N-Ac cysteine, L-cystine, Nicotinamide, Taurursodiol
|
2 |
|
Dallas VA Medical Center |
| 7 |
ranolazine
|
2 |
- placebo controlled trial evaluating two doses of ranolazine
- sites in CA, FL, KS, OH, MO
|
Swathy Chandrashekhar, MBBS |
| 8 |
istradefylline and acute intermittent hypoxia
|
1/2 |
- crossover study: all trial volunteers will receive placebo and all trial volunteers will receive active treatment at different timepoints
- sites in FL
|
University of Florida |
| 9 |
prosetin
|
1 |
- placebo controlled trial lasting 14 days followed by open label extension
- oral drug designed to target MAP4 kinase
- site in MA
|
ProJenX |
| 10 |
Psilocybin
|
1 |
|
Johns Hopkins University |
| 11 |
AMX0114
|
1 |
- 25% chance of placebo
- antisense oligoneucleotide not limited to genetic ALS and designed to target calpain 2
- intrathecal delivery of up to 4 doses
- sites in CA, DC, FL, MA, MN, PA, TN, TX
|
Amylyx Pharmaceuticals Inc. |
| 12 |
acamprosate
|
1 |
- no placebo
- recruiting people with C9orf72-related ALS
- site in MD
|
National Institute of Neurological Disorders and Stroke (NINDS) |
| 13 |
RAPA-501
|
EAP |
- Expanded Access Program for people that are not eligible for trials
- Autologous hybrid TREG/Th2 cells delivered intravenously
- sites in AZ, CA, GA, IA, MA, MN, NJ, OR
|
Rapa Therapeutics LLC |
| 14 |
SPG302
|
EAP |
- Expanded Access Program for people that are not eligible for trials
- Once a day oral pill that aims to restore synapses
- Sites in IL, MA, NJ
|
Spinogenix |
| 15 |
MN-166 (ibudilast)
|
EAP |
- Expanded Access Program for people that are not eligible for trials
- Contact WideTrial to join interest list to participate and see additional contact info here
- Site in AZ, CA, CT, FL, IN, MN, NC, TN, VA
|
Mayo Clinic |